Verrica Pharmaceuticals (VRCA) Free Cash Flow (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Free Cash Flow of -$9.2 million for Q1 2026, up 27.43% year-over-year from -$7.2 million in Q1 2025, and down 100.0% quarter-over-quarter from -$4.6 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Free Cash Flow (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$9.2 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 27.43% year-over-year to -$9.2 million; the TTM figure through Mar 2026 stood at -$14.1 million (up 73.69% YoY), while the FY2025 annual figure was -$17.6 million, up 71.13% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$9.2 million, down from -$4.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $9.7 million in Q3 2025, with the low at -$19.9 million in Q1 2024.
- The 5-year median for Free Cash Flow is -$8.6 million (2024), against an average of -$8.6 million.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow slumped 951.03% in 2023, then soared 213.38% in 2025.
- Verrica Pharmaceuticals' Free Cash Flow stood at -$5.0 million in 2022, then slumped by 193.51% to -$14.7 million in 2023, then decreased by 9.03% to -$16.1 million in 2024, then soared by 71.36% to -$4.6 million in 2025, then sank by 100.0% to -$9.2 million in 2026.
- Business Quant data shows VRCA's Free Cash Flow at -$9.2 million in Q1 2026, -$4.6 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -9.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.24 Mn |
| Jun 30, 2026 | -9.24 Mn |
| Mar 31, 2026 | -9.20 Mn |
| Mar 31, 2026 | -9.20 Mn |
| Dec 31, 2025 | -4.60 Mn |
| Dec 31, 2025 | -4.60 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Jun 30, 2025 | -10.04 Mn |
| Jun 30, 2025 | -10.04 Mn |
| Mar 31, 2025 | -12.68 Mn |
| Mar 31, 2025 | -12.68 Mn |
| Dec 31, 2024 | -16.06 Mn |
| Dec 31, 2024 | -16.06 Mn |
| Sep 30, 2024 | -8.57 Mn |
| Sep 30, 2024 | -8.57 Mn |
| Jun 30, 2024 | -16.37 Mn |
| Jun 30, 2024 | -16.37 Mn |
| Mar 31, 2024 | -19.95 Mn |
| Mar 31, 2024 | -19.95 Mn |